- Home
- » Tags
- » Daclatasvir
Top View
- The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection
- Póster EAHP 2018
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- (Daklinza®, DCV) 60 Mg
- Daclatasvir – Benefit Assessment According 1 to §35A Social Code Book V
- Dual Therapy with the Nonstructural Protein 5A Inhibitor, Daclatasvir, And
- Sofosbuvir with Daclatasvir and the Outcomes of Patients with COVID-19
- Antiviral Therapeutic Approaches for SARS-Cov-2 Infection: a Systematic Review
- Summary on Compassionate Use For
- 206843Orig1s000
- Targeting Hepatitis C Virus P7 Channel Activity Reveals Prospect for Bimodal
- UNIVERSITE TOULOUSE III - Paul SABATIER
- Updates in Hepatitis C Treatment
- Medical Product Quality Report – COVID-19 Issues
- Fixed-Dose Combination Therapy with Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients with HCV Genotype 1 Infection
- Anatomisch-Therapeutisch- Chemische Klassifikation Mit Tagesdosen Für
- Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV Infection
- Approved Antiviral Drugs Over the Past 50 Years
- Ongoing Living Update of COVID-19 Therapeutic Options
- Report on the Deliberation Results November 16, 2016
- Daklinza (Daclatasvir)
- Title • Rationally Derived Inhibitors of Hepatitis C Virus
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Modeling Shows That the NS5A Inhibitor Daclatasvir Has Two Modes of Action and Yields a Shorter Estimate of the Hepatitis C Virus Half-Life
- 20219 WHO Living Guideline -Therapeutics and COVID-19
- Olysio, INN-Simeprevir
- Pharmaceuticals and Medical Devices Safety Information No
- Daclatasvir PK Fact Sheet Reviewed March 2016 Page 1 of 2 for Personal Use Only
- WHO R&D Blueprint
- Remdesivir from Wikipedia, the Free Encyclopedia
- Daclatasvir in Combination with Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection with Compensated Cirrhosis
- Daclatasvir (Daklinza)
- Daclatasvir/Sofosbuvir (Daklinza®/Sovalditm) Drug Interactions a Quick Guide for Clinicians – April 2017
- SOFOSBUVIR/DACLATASVIR V C S , Us
- In Silico Docking for Inhibition Neuropilin-1 (Sars-Cov-2 Receptor)
- (HCV) P7 Channel Activity Reveal Prospect for Bimodal Antiviral Therapy
- Daklinza™ (Daclatasvir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment
- Original Article Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1
- DAKLINZA™ DACLATASVIR Tableta
- Daklinza™ (Daclatasvir) & Sovaldi® (Sofosbuvir) Treatment Agreement
- EASL Recommendations on Treatment of Hepatitis C 2015
- Beschlussfassung Der Arbeitsgruppe ATC/DDD Des Kuratoriums Für Fragen Der Klassifikation Im Gesundheitswesen
- ESAC-Net Reporting Protocol 2018.Docx Introduction
- Daclatasvir, an Efficient Inhibitor of the Hepatitis C Virus Replication Complex Protein NS5A: Review of Virologic Data, Treatment Rationale and Clinical Trials